ARK Genomic Revolution ETF Newsroom

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500

Benzinga03:23

Bernstein Maintains Outperform on Natera, Raises Price Target to $135

BenzingaOct 31 02:59 · Ratings

Natera Shares Are Trading Higher After Canaccord Genuity Maintained a Buy Rating on the Stock and Raised Its Price Target From $145 to $150.

BenzingaOct 30 01:41

Looking Into Intellia Therapeutics's Recent Short Interest

BenzingaOct 29 21:45

Baird Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $18

BenzingaOct 25 20:23 · Ratings

Intellia Therapeutics Analyst Ratings

BenzingaOct 25 05:42 · Ratings

UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus

Seeking AlphaOct 25 03:32

A Closer Look at Intellia Therapeutics's Options Market Dynamics

BenzingaOct 25 02:45

Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?

BenzingaOct 25 00:43

3 Health Care Stocks Moving In Thursday's Intraday Session

BenzingaOct 25 00:37

Intellia Slips After Mid-stage Data for CRISPR-based Hereditary Angioedema Therapy

Seeking AlphaOct 24 21:14

UBS Initiates Coverage On Nurix Therapeutics With Buy Rating, Announces Price Target of $35

BenzingaOct 24 19:46 · Ratings

Ionis And AstraZeneca's WAINZUA Recommended For EU Approval As First Self-Administered Treatment For HATTR-PN

BenzingaOct 21 14:53

Twist Bioscience Analyst Ratings

BenzingaOct 17 22:55 · Ratings

Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock

BenzingaOct 17 11:19

Veracyte Started at Buy by UBS, MRD Platform Cited

Seeking AlphaOct 17 02:29

Natera Analyst Ratings

BenzingaOct 16 21:37 · Ratings

CareDx Analyst Ratings

BenzingaOct 16 21:30 · Ratings

Crude Oil Tumbles 5%; Goldman Sachs Earnings Top Views

BenzingaOct 15 23:57

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BenzingaOct 15 20:08